10-K: Bio-Techne Reports Mixed FY25 Results Amid Restructuring

Bio-Techne Corporation reported a 5% increase in net sales to $1.2 billion for fiscal year 2025, but GAAP net earnings decreased 56% due to non-recurring charges, while adjusted net earnings grew 8%.

Summary

• Consolidated net sales for fiscal year 2025 increased 5% to $1.2 billion, with organic growth also at 5%.
• GAAP consolidated net earnings for fiscal 2025 decreased 56% compared to fiscal 2024, primarily due to a non-recurring arbitration award, impairment of assets held-for-sale, and restructuring charges.
• Adjusted net earnings for fiscal 2025 increased 8% compared to fiscal 2024, driven by favorable volume leverage within the Protein Sciences segment.
• The Protein Sciences segment, representing 72% of net sales, saw a 5% increase in net sales in fiscal 2025, driven by proteomic analytical solutions and cell therapy performance.
• The Diagnostics and Spatial Biology segment, representing 28% of net revenues, experienced a 6% increase in net sales in fiscal 2025, with organic growth of 6% attributed to molecular diagnostics and Lunaphore's performance.
• Consolidated gross margins were 64.8% in fiscal 2025, down from 66.4% in fiscal 2024, impacted by incentive accruals and product mix.
• Selling, general and administrative expenses increased $122.1 million (26%) in fiscal 2025, largely due to a non-recurring arbitration award and impairment of assets held-for-sale.
• Research and development expenses increased 3% to $99.5 million in fiscal 2025, primarily due to strategic growth investments.
• The company repurchased 4,550,195 shares totaling $275.7 million in fiscal 2025, and the Board approved a new $500 million share repurchase plan on April 30, 2025.
• A definitive agreement was announced on August 5, 2025, to sell the Exosome Diagnostics business for $15 million, expected to close in Q1 fiscal 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While net sales and adjusted earnings show growth, the significant decline in GAAP net earnings due to substantial non-recurring charges (arbitration award, asset impairment, restructuring) and a decrease in gross margin present a mixed financial picture. Strategic acquisitions and share repurchases are positive, but the immediate financial impact of these charges and the sale of a business temper overall optimism.

Positives

• Consolidated net sales increased 5% to $1.2 billion in fiscal 2025, with strong organic growth of 5%.
• Adjusted net earnings increased 8% in fiscal 2025, indicating underlying operational strength despite non-recurring charges.
• The Protein Sciences segment demonstrated strong commercial execution and performance in proteomic analytical solutions and cell therapy, with 5% net sales growth.
• The Diagnostics and Spatial Biology segment achieved broad-based molecular diagnostics performance and organic growth from Lunaphore, contributing to a 6% increase in net sales.
• The company continues to invest in strategic acquisitions and partnerships, such as the investment in Spear Bio in fiscal 2025 and the planned full acquisition of Wilson Wolf by end of calendar year 2027.
• Cash generated from operations remained strong at $287.6 million in fiscal 2025.
• The company maintains a strong balance sheet with $654.0 million of unutilized availability under its revolving credit facility as of June 30, 2025.
• Significant share repurchases totaling $275.7 million in fiscal 2025 demonstrate commitment to returning capital to shareholders, supported by a new $500 million repurchase plan.

Negatives

• GAAP consolidated net earnings decreased significantly by 56% in fiscal 2025 compared to fiscal 2024.
• A non-recurring arbitration award of $37.2 million (inclusive of interest and legal fees) was paid in Q3 fiscal 2025 to a former CEO, impacting earnings.
• Impairment of assets held-for-sale resulted in a charge of $80.5 million in fiscal 2025, primarily from the Exosome Diagnostics business.
• Restructuring and restructuring-related charges totaled $95.6 million in fiscal 2025, including asset impairments and employee severance.
• Consolidated gross margins declined to 64.8% in fiscal 2025 from 66.4% in fiscal 2024, affected by incentive accruals and unfavorable product mix.
• Net interest expense was ($4.6) million in fiscal 2025, although an improvement from ($12.4) million in fiscal 2024, still represents a cost.
• The effective GAAP tax rate increased to 25.5% in fiscal 2025 from 9.5% in fiscal 2024, partly due to share-based compensation and executive compensation limitations.

Risks

• Global economic conditions, including slower growth, inflation, recession, and market volatility, may adversely affect business and financial results.
• International political, compliance, and business factors, such as conflicts in Ukraine and Gaza, and trade tensions between the U.S. and China, can negatively impact operations and financial results, especially given 44% of fiscal 2025 sales were outside the U.S.
• The healthcare and life sciences industries face constant pressures to reduce costs, which may adversely affect demand for products and government funding for research.
• Inability to complete acquisitions at historical rates and appropriate prices, or to integrate acquired businesses effectively, could negatively impact growth and financial results.
• Reliance on internal manufacturing and distribution systems means disruptions due to catastrophes, supply chain issues, or quality control problems could seriously harm operations.
• Intense competition across product lines from diverse competitors, including large global companies and niche players, could lead to decreased demand, market share, or pricing pressures.
• Significant disruption or breach of information technology systems or data, or violation of data privacy laws (e.g., HIPAA, GDPR, CCPA), could result in reputational damage, costs, fines, or lawsuits.
• Dependence on maintaining intellectual property rights, with risks of challenges, invalidation, or infringement by third parties, particularly in countries with less protective laws.
• Exposure to foreign currency exchange rate fluctuations, as a substantial portion of revenues are international, could adversely affect reported revenues and profitability.
• Changes in tax laws or related interpretations, including potential future impacts from the 'One Big Beautiful Bill Act', could adversely affect the effective tax rate and financial results.
• Extensive regulation in medical device, healthcare, import/export, anticorruption, and privacy areas means failure to comply could adversely affect business and financial results, including potential penalties or debarment from government contracts.
• Improper conduct by employees, agents, or business partners, including violations of anti-bribery laws like the U.S. Foreign Corrupt Practices Act, could damage reputation and lead to significant penalties.

Future Outlook

The company plans capital additions of approximately $42 million for fiscal 2026, to be financed through available cash and cash generated from operations. The acquisition of the remaining 80.1% ownership in Wilson Wolf, estimated at approximately $1 billion plus potential contingent consideration, is forecasted to occur between fiscal 2026 and fiscal 2028, with potential acceleration if certain financial milestones are met. The company expects gross margins to continue to be impacted by product mix and future acquisitions.

Management Comments

• Management believes future success depends on the ability to keep pace with changing technologies and market needs, and is engaged in continuous research and development.
• Management is committed to attracting, developing, engaging, and retaining top talent globally, fostering an 'EPIC' culture based on Empowerment, Passion, Innovation, and Collaboration.
• Management expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available funds and cash generated from operations.

Industry Context

Bio-Techne operates in highly competitive and rapidly evolving life science and diagnostics markets, characterized by rapid technological change and frequent new product introductions. The company's strategy of growth through innovation and acquisition, particularly in high-potential areas like cell and gene therapy and spatial biology, aligns with broader industry trends focusing on advanced research tools and precision diagnostics. The industry also faces constant pressure to reduce healthcare costs and navigate complex global regulatory environments, which Bio-Techne addresses through its diverse product portfolio and compliance efforts.

Comparison to Industry Standards

• The company's strategic investment in Spear Bio and acquisition of Lunaphore SA, a developer of automated spatial biology solutions, positions it strongly in the high-growth spatial biology market, a key area of innovation for competitors like 10x Genomics and NanoString Technologies.
• The planned full acquisition of Wilson Wolf, a leading provider of cell culture devices, strengthens Bio-Techne's offering in the rapidly expanding cell and gene therapy market, competing with companies such as Thermo Fisher Scientific and Sartorius.
• The ExoDx Prostate test, an exosome-based liquid biopsy for prostate cancer detection, places Bio-Techne in the competitive liquid biopsy diagnostics space, alongside players like Exact Sciences (Cologuard) and Guardant Health, aiming for early detection and reduced invasive procedures.

Management Changes

Corporate Governance

Legal Proceedings

• A dispute with a former CEO regarding the expiration date of outstanding vested stock options was resolved through a binding arbitration award during the quarter ended March 31, 2025. The company paid $37.2 million, inclusive of interest and legal fees.
• A dispute regarding 12,120 shares of other former employees' options was resolved during the quarter ended March 31, 2025, resulting in total payments of $0.5 million.
• The company is involved in various legal actions from time to time, including product liability, employment, intellectual property, commercial disputes, shareholder matters, environmental proceedings, tax disputes, and governmental investigations. The outcomes are inherently uncertain, and costs could materially impact financial results.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in GAAP net earnings but an increase in adjusted net earnings. Benefit from continued dividends and substantial share repurchases. The arbitration award and restructuring charges negatively impacted reported earnings.
• Employees: Impacted by restructuring actions in fiscal 2024 and 2025, which included employee severance. The company is committed to attracting and retaining talent through an 'EPIC' culture and expanded equity incentive programs.
• Customers: Benefit from continuous research and development, new product introductions (over 400 in fiscal 2025), and expanded global sales and distribution channels. The sale of Exosome Diagnostics may affect certain diagnostic customers.
• Suppliers: The company's reliance on sole or limited source suppliers for certain materials poses a risk of production interruptions if suppliers face difficulties.
• Regulatory Bodies: The company is subject to extensive regulation (FDA, CLIA, HIPAA, GDPR, anti-corruption laws), and non-compliance could lead to penalties and operational restrictions.

Next Steps

• Close the definitive agreement to sell the Exosome Diagnostics business during the first quarter of fiscal 2026.
• Finance approximately $42 million in planned capital additions for fiscal 2026 through currently available cash and cash generated from operations.
• Acquire the remaining 80.1% ownership in Wilson Wolf by December 31, 2027, or earlier if certain financial milestones are met, with an estimated payment of approximately $1 billion plus potential contingent consideration.
• Continue to implement enterprise-wide restructuring actions through fiscal 2026 to optimize global manufacturing processes and organizational efficiency.
• Monitor and comply with new accounting pronouncements, including ASU 2023-07 (Improvements to Reportable Segment Disclosures) adopted in this report, ASU 2023-09 (Improvements to Income Tax Disclosures) to be adopted in Q4 fiscal 2026, and ASU 2024-03 (Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures) to be adopted in fiscal 2027.

Key Dates

Recommendation

While Bio-Techne demonstrated solid organic sales growth and an increase in adjusted net earnings, the significant decline in GAAP net earnings due to substantial non-recurring charges (arbitration award, asset impairment, restructuring) creates uncertainty. The company's strategic acquisitions and share repurchases are positive long-term indicators, but the immediate financial impact of these charges and the ongoing restructuring efforts warrant a cautious 'hold' stance. Investors should monitor the successful integration of acquisitions, the realization of benefits from restructuring, and the impact of the Exosome Diagnostics divestiture before considering a stronger position.

Keywords

Life Sciences, Diagnostics, Bioprocessing, Reagents, Instruments, Cell and Gene Therapy, Spatial Biology, Molecular Diagnostics, Exosome Diagnostics, Protein Sciences, Biotechnology, SEC Filing, 10-K, Financial Results, Acquisitions, Restructuring, Corporate Governance